Kodiak Sciences : Corporate Presentation (dated May 2021)

NASDAQ: KOD KODIAK.COM

THE OPHTHALMOLOGY MEDICINES COMPANY

MAY 2021

S P E C I A L N O T E R E G A R D I N G

FORWARD-LOOKING STATEMENTS

These slides contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding our 2022 Vision; our ability to submit a BLA for KSI-301 in

wet AMD, DME, RVO and potentially diabetic retinopathy in end 2022 or early 2023; the potential licensure of KSI-301 in the U.S. and EU in 2023; our platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof; the anticipated design of our clinical trials and regulatory submissions; expectations regarding the potential efficacy and commercial prospects of our product candidates; the anticipated presentation of additional data; the results of our research and development efforts; and our ability to advance our product candidates into later stages of development and potential commercialization. All forward-looking statements are based on management's current expectations, and future events are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the safety, efficacy and durability data for our KSI-301 product candidate may not continue or persist; cessation or delay of any of the ongoing clinical studies and/or our development of KSI-301 may occur, including as a result of the ongoing COVID-19 pandemic; future potential regulatory milestones of KSI-301, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; anticipated presentation of data at upcoming conferences may not occur; our research and development efforts and our ability to advance our product candidates into later stages of development may fail; any one or more of our product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets, including the ongoing COVID- 19 pandemic, which may significantly impact our business and operations, including out of our headquarters in the San Francisco Bay Area and our clinical trial sites, as well as the business or operations of our manufacturers, contract research organizations or other third parties with whom we conduct business; as well as the other risks identified in our filings with the Securities and Exchange Commission. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

2

K O D I A K S C I E N C E S

WHERE WE ARE TODAY

6 P I V O T A L C L I N I C A L T R I A L S

T O P L I N E D A T A

E X P E C T E D I N 2 0 2 2 :

• D A Z Z L E 1 Q
• B E A C O N 2 Q
• G L E A M & G L I M M E R 4 Q
• D A Y L I G H T 4 Q

K S I - 3 0 1 C L I N I C A L E X P E R I E N C E

Clinical data from ~2,500 injections in ~500 patients representing ~450 patient-years of exposure in representative populations in wAMD, DME and RVO

• Safety: Tracking with current standard of care (Lucentis, Eylea)
• Efficacy: Vision & retinal anatomy improvements in line with current anti-VEGF agents
• Durability: 2 in every 3 patients going 6-months or longer between doses

O P T I M I Z E D P I V O T A L S T U D Y P R O G R A M

Objective to show disruptive durability with same safety and efficacy as Eylea

DAZZLE wet AMD study enrollment complete; BEACON RVO study and GLEAM & GLIMMER DME now enrolling, DAYLIGHT label broadening study First Patient In 3Q2021 - Data from all studies expected in 2022

Pivotal studies designed from phase 1b data with high dose (5.0 mg), high statistical power, tighter criteria for disease activity assessments, tighter dosing interval ranging, maintaining similar (80%+) U.S. treatment naïve population

O P E R A T I N G W I T H C O N V I C T I O N

On track for single BLA in the key indications of wAMD, DME, RVO treatment and NPDR in a supplemental Manufacturing investments aligned to clinical opportunity with commercial supply goal of 2.5M+ in Year 1

Pipeline bispecific and triplet ABC Medicines for multi-mechanism diseases, including dry AMD and glaucoma

B L A F I L I N G E X P E C T E D

E N D 2 0 2 2 O R E A R L Y 2 0 2 3

P O I S E D C O M M E R C I A L O P P O R T U N I T Y

Competitive landscape is clearing with competing technologies demonstrating poor risk-benefit profiles

Pivotal clinical study package at initial BLA designed for very broad dosing label from 1-month to 5/6-month and deliver reimbursement confidence and first-line-agent status for every wAMD, DME, RVO, NPDR patient

We believe KSI-301 may be able to capture market share from standard of care agents, future biosimilars, and competing late-stage molecules in development

3

T H E O P H T H A L M O L O G Y M E D I C I N E S C O M P A N Y

OUR MISSION

1 TRAILBLAZING	2 GENERATION 2 . 0	3	SINGULAR FOCUS IN
SCIENCE	MEDICINES		OPHTHALMOLOGY
Our creative and	Our challenge to the		Our 24 / 7 / 365
thoughtful foundation	status quo

4

1. PIPELINE OF ABCS FOR RETINA

Kodiak's deepening pipeline of mono-,bi-specific and triplet inhibitors that merge biologics with small molecules to address major causes of vision loss beyond retinal vascular disease

M O N O S P E C I F I C

1 Molecule, 1 Target

Antibody conjugated to phosphorylcholine biopolymer

KSI-301 inhibits VEGF-

In Phase 3 clinical development

B I S P E C I F I C

1 Molecule, 2 Targets

Bispecific antibody conjugated to phosphorylcholine biopolymer

KSI-501 inhibits VEGF and IL-6 for retinal diseases with inflammatory component - IND planned 1H2022

T R I P L E T

1 Molecule, 3 Targets

Bispecific antibody conjugated to phosphorylcholine

biopolymer embedded with 100's of copies of small- molecule drug

KSI-601 for high-prevalence multifactorial diseases, such as dry AMD - IND planned 2022

5